TD Cowen Upgrades PTC Therapeutics to Buy, Raises Price Target to $90
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $75 to $90.
TD Cowen analyst Joseph Thome upgrades PTC Therapeutics (NASDAQ:PTCT) from Hold to Buy and raises the price target from $75 to $90.